Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROS1 | P08922 | 6/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.68 |
| ▸ | EGFR | P00533 | 13/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904648 | 1.00 | ROS1 (0.68) | ROS1ALKEGFRLRRK2MAPK3 | |
| SCHEMBL27119073 | 0.86 | ROS1 (0.70) | ROS1ALKEGFRLRRK2 | |
| SCHEMBL29904633 | 0.86 | ROS1 (0.70) | ROS1ALKEGFRLRRK2 | |
| SCHEMBL29904635 | 0.85 | ALK (0.62) | ROS1ALKEGFRLRRK2 | |
| SCHEMBL26906635 | 0.85 | ALK (0.62) | ROS1ALKEGFRLRRK2 | |
| SCHEMBL27115493 | 0.85 | ALK (0.75) | ROS1ALKEGFRLRRK2 | |
| SCHEMBL29904632 | 0.85 | ALK (0.71) | ROS1ALKEGFRMET | |
| SCHEMBL26906765 | 0.85 | ALK (0.71) | ROS1ALKEGFRMET | |
| SCHEMBL29904621 | 0.84 | ALK (0.68) | ROS1ALKEGFR | |
| SCHEMBL26906503 | 0.84 | ALK (0.68) | ROS1ALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | claimed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | claimed |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | ROS1 117/4885ALK 120/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.